MS

Showing 15 posts of 92 posts found.

Rilutek (riluzole) image

Multiple sclerosis studies underway using existing drugs

April 2, 2015
Research and Development, Sales and Marketing MS, Midamor, Prozac, Rilutek, Sanofi, amiloride, covis, fluoxetine, multiple sclerosis, riluzole

Three existing drugs that fight heart disease, depression and motor neurone disease could be used to treat multiple sclerosis (MS) …

Google image

J&J and Google partner to build surgical robots

March 30, 2015
Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots

The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …

Biogen image

Biogen shortens name and posts positive Alzheimer’s results

March 23, 2015
Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec

Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …

Google image

Google partners with Biogen on multiple sclerosis

January 30, 2015
Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos

Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …

Biogen Idec image

Mixed results for Biogen’s MS drug

January 9, 2015
Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy

An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …

Sativex image

Late-stage failure for Otsuka and GW cancer pain drug

January 9, 2015
Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …

Genzyme image

FDA green lights Lemtrada for MS

November 17, 2014
Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera

The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …

Teva image

Teva to ditch R&D in cancer and women’s health

October 6, 2014
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, MS, R&D, Teva, cuts, generics

Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and …

Biogen image

FDA approves Biogen’s long-acting MS drug

August 18, 2014
Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera

Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …

Roche image

Roche to launch new MS collaboration

June 23, 2014
Research and Development, Sales and Marketing MS, Roche, inception sciences, multiple sclerosis, versant ventures

Roche has launched a new research collaboration to investigate ways of reversing the debilitating nerve damage caused by multiple sclerosis …

sanofi image

Lemtrada resubmitted to FDA

June 2, 2014
Sales and Marketing FDA, Lemtrada, MS, Sanofi

Sanofi has resubmitted its application for Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis (MS) to the …

Biogen Idec image

Biogen Idec’s MS drug gets European approval

February 4, 2014
Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera

Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …

screen_shot_2014-01-29_at_10

High-dose Copaxone the right medicine for Teva

January 29, 2014
Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva

The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …

Teva image

Teva’s Great White Hope knocked back by Europe

January 27, 2014
Sales and Marketing CHMP, EU, MS, Nerventra, Teva

The drug designed to be a follow-up to Teva’s wildly successful Copaxone has been hit by rejection in Europe, leaving …

The Gateway to Local Adoption Series

Latest content